Most in the healthcare industry have begun to hear more about longevity – an area of medical science that has the ability to dramatically improve well-being for all of humanity. With the advancements in understanding human biology at the cellular level, researchers and scientists have pinpointed specific areas that can be treated to improve or extend critical bodily functions. One of the organizations that is pioneering new technology in the longevity space is Juvenescence, a biopharmaceutical company that has raised over $100 million to build a pipeline of therapeutic assets.
Interestingly, Juvenescence has not been around for that long. It was founded in 2017 and already supports ten companies. Its CEO is Dr. Gregory Bailey who has comprehensive experience in healthcare, finance and medicine. Currently, he is chairman of Portage Biotech, a publicly traded drug development companies and was previously managing partner of Palantir Group, Inc., a merchant bank specializing in biotech and intellectual property.
Regarding the company’s recent funding round, he had this to say, “This has been such an exciting six months for Juvenescence. We have been able to add extraordinary people to the Juvenescence team who will bring our age modifying therapeutics to market. We have also augmented our team working on using machine learning for drug discovery and for drug development: culminating with closing on this $100 Million Series B financing which provides us with sufficient working capital to progress many of our programs to their initial inflection points”.
The round also included $10 million from its founder and an additional $10 million each from four cornerstone investors, including Grok Ventures, the investment company of Mike Cannon-Brookes (Atlassian cofounder), and Michael Spencer’s private investment company, IPGL.
Juvenescence chairman Jim Mellon also commented, “We have recruited a group of sophisticated shareholders from around the world to further our common mission of improving human healthy lifespan. Juvenescence has now raised more money than any comparable company, which is testament to the depth of our team and the range of opportunities that we have assembled, in partnership with scientist/entrepreneurs and research institutions. As the science of longevity becomes mainstream, we expect significant investor interest and at some point, we anticipate taking Juvenescence public to further accelerate our development.”
Among the key biological areas of focus are epigenetic alterations, telomere attrition, mitochondrial dysfunction, stem cell exhaustion and altered intracellular communication. A key element within the company’s ecosystem is its use of artificial intelligence and machine learning techniques to discover and develop new drugs while working in conjunction with key partners.